Bedfont Scientific Ltd., a global leader in breath analysis with a rich history spanning five decades, is preparing to make a significant impact at the upcoming United European Gastroenterology (UEG) Week 2026 in Barcelona. The company plans to unveil its cutting-edge Gastrolyzer range, specifically designed for hydrogen and methane breath testing, to a global audience of digestive health professionals. This strategic participation aims to spotlight their non-invasive breath testing solutions for a variety of gastrointestinal disorders, reinforcing their commitment to innovation and improved patient care within the digestive health community.
Bedfont's Pioneering Breath Analysis Takes Center Stage at UEG Week 2026
From October 17th to 20th, 2026, the Fira Gran Via in Barcelona will host the prestigious UEG Week, an assembly point for over 11,000 specialists from the global digestive health sector. Bedfont Scientific Ltd., boasting over 30 years of expertise in hydrogen and methane breath testing (HMBT) with its renowned Gastrolyzer devices, will be a key exhibitor at stand 29. The company's objective is to raise global awareness about the crucial role of its non-invasive breath analysis technology in the diagnosis and management of gastrointestinal conditions.
Jason Smith, CEO of Bedfont, emphasized the global significance of enhancing access to effective digestive health diagnostics, noting that over 40% of the world's population is estimated to suffer from functional gastrointestinal disorders. He articulated Bedfont's belief in the transformative potential of breath analysis to offer healthcare professionals a simple and non-invasive tool for investigating digestive health. Mr. Smith views UEG Week as an unparalleled platform for engaging with the international gastroenterology community, sharing knowledge, and showcasing how the Gastrolyzer portfolio can substantially elevate patient care.
The Gastrolyzer line, a cornerstone in gastrointestinal diagnostics for more than 35 years, includes the compact, portable hydrogen-detecting Gastro+, and the desktop-based GastroCH4ECK, which facilitates both hydrogen and methane breath tests, including remote testing capabilities. Attendees will have the opportunity to experience live demonstrations of these devices.
Dr. Jafar Jafari, Head of Upper Gastrointestinal Physiology at Guy’s and St Thomas’ and a distinguished member of Bedfont’s Medical Advisory Board, will join the Bedfont team in Barcelona. Dr. Jafari, also the founder of GI Cognition, will be available from October 18th to 20th to discuss his authoritative work, 'The Essential Guide to Hydrogen and Methane Breath Testing,' offering invaluable clinical insights and expertise directly from the Bedfont stand.
This event marks a pivotal moment for Bedfont to further solidify its position as an innovator in medical diagnostics and to collaborate with healthcare providers worldwide in tackling the complexities of digestive health.
The proactive engagement by Bedfont Scientific Ltd. at such a prominent international forum highlights a forward-thinking approach to healthcare. By championing non-invasive diagnostic methods like breath analysis, the company not only simplifies the diagnostic process for patients but also empowers healthcare professionals with efficient and accurate tools. This initiative reflects a broader commitment within the medical technology sector to move towards less intrusive yet highly effective solutions. The collaboration with leading clinicians, like Dr. Jafar Jafari, further enriches the scientific discourse and ensures that technological advancements are firmly rooted in clinical relevance and patient benefit. This blend of innovation and clinical application holds the promise of significantly improving the diagnostic landscape for gastrointestinal disorders globally, ultimately enhancing the quality of life for millions affected by these conditions.